The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pulmonary edema, noncardiogenic (NCPE)
Publications
A Man with Severe Pulmonary Hypertension and Right Ventricular Failure.
Annals of the American Thoracic Society 2018 Dec;15;1472-1476 — 2018 Dec — 1472-1476
Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jöbsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.
Annals of internal medicine 2000 Mar 21;132;425-34 — 2000 Mar 21 — 425-34
Pulmonary edema complicating prostacyclin therapy in pulmonary hypertension associated with scleroderma: a case of pulmonary capillary hemangiomatosis.
Arthritis and rheumatism 2000 Mar;43;699-703 — 2000 Mar — 699-703
Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study.
The European respiratory journal 1999 Jun;13;1351-6 — 1999 Jun — 1351-6
Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis.
American journal of respiratory and critical care medicine 1998 May;157;1681-5 — 1998 May — 1681-5